Trials / Completed
CompletedNCT05337345
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Cendakimab Administered Using Autoinjector Versus Using Prefilled Syringe, and to Evaluate the Pharmacokinetics of Cendakimab When Administered by Autoinjector at Different Injection Sites, in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cendakimab | Specified Dose on Specified Days |
Timeline
- Start date
- 2022-05-02
- Primary completion
- 2022-12-15
- Completion
- 2022-12-15
- First posted
- 2022-04-20
- Last updated
- 2023-02-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05337345. Inclusion in this directory is not an endorsement.